NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
NovaBridge Biosciences - American Depositary Shares (NBP)
Company Research
Source: PR Newswire
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistanceThe study achieved its objective, as the new Q6W extended dosing interval produced encouraging anti-tumor efficacy and immunological data in prior immune-oncology refractory or relapsed patients including anti-PD- (L)1 checkpoint inhibitor, with improved safety, compared to the prior Q2W scheduleThe poster includes positive immunological data on CD8+ cell proliferation and memory T-cell activationROCKVILLE, Md., Dec. 11, 2025 /PRNewswire/ -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced the presentation of new data from the expanded 3mg/kg every 6 week (Q6W) Phase 1 dosing study for
Show less
Read more
Impact Snapshot
Event Time:
NBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBP alerts
High impacting NovaBridge Biosciences - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NBP
News
- Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial ShareholderPR Newswire
- NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO [Yahoo! Finance]Yahoo! Finance
- NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IOGlobeNewswire
- NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IOPR Newswire
- NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IOGlobeNewswire
NBP
Sec Filings
- 12/18/25 - Form 144
- 12/18/25 - Form 6-K
- 12/10/25 - Form 6-K
- NBP's page on the SEC website